Overview

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and < 110 mmHg).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Amlodipine
Hydrochlorothiazide